EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Ryan B. Corcoran, Hiromichi Ebi, Alexa B. Turke, +13

Cancer Discovery

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

Dennie T. Frederick, Adriano Piris, Alexandria P. Cogdill, +18

Clinical Cancer Research

Toward Minimal Residual Disease-Directed Therapy in Melanoma

Florian Rambow, Aljosja Rogiers, Oskar Marín-Béjar, +22

Cell

Novel TherapyMedicineMelanomaDermatologyOncology +2

<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Russell W. Jenkins, Amir Reza Aref, Patrick H. Lizotte, +81

Cancer Discovery

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

David J. Konieczkowski, Cory M. Johannessen, Omar O. Abudayyeh, +14

Cancer Discovery

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

Filiberto Belli, Alessandro Testori, Licia Rivoltini, +25

Journal of Clinical Oncology

<i>RAS</i> Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

Patrick A. Oberholzer, Damien Kee, Piotr Dziunycz, +14

Journal of Clinical Oncology

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

Zachary A. Cooper, Vikram R. Juneja, Peter T. Sage, +12

Cancer Immunology Research

ImmunologyImmune RegulationImmunoeditingMelanoma Is EnhancedCd4 T Cell Responses +22

Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families

Ching-Ni Jenny Njauw, Ivana K. Kim, Adriano Piris, +7

PLoS ONE

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Roberta Mortarini, Adriano Piris, Andrea Maurichi, +10

PubMed

ImmunologyImmunoeditingAntitumor ImmunityT CellsImmunotherapy +14